Non-human animal cells and non-human animals comprising a humanized Asgr1 locus and methods of using such non-human animal cells and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized Asgr1 locus express a human ASGR1 protein or an Asgr1 protein, fragments of which are from human ASGR1. Methods are provided for using such non-human animals comprising a humanized Asgr1 locus to assess in vivo efficacy of human-ASGR1-mediated delivery of therapeutic molecules or therapeutic complexes to the liver and to assess the efficacy of therapeutic molecules or therapeutic complexes acting via human-ASGR1-mediated mechanisms.

Methods are described for differentiating stem and post-natal cells into sex hormone-producing cells that can be administered to a patient autologously or allogeneically in order to maintain in balance, or rebalance, their hypothalamic-pituitary-gonadal (HPG) axis.

A drug used for treating ischemia and hypoxia-induced tissue necrosis or for improving cardiac function; the drug contains amniotic fluid from a non-human animal and/or an extract thereof, and an optional pharmaceutically acceptable carrier, wherein the amniotic fluid comes from chicken eggs having an embryonic age of 5-12 days, eggs from other birds corresponding to the described developmental period, embryos from rodents having a gestational age of 8-20 days, or embryos from other non-human mammals corresponding to the described developmental period. The drug may promote the growth of human umbilical vein endothelial cells, AC16 cells and chicken embryo fibroblasts, improve cardiac function after myocardial infarction, and promote cardiac cell regeneration after a myocardial infarction.

The present application provides a method for an assisted reproductive technology comprising using a medium comprising a low caprylic acid-containing albumin; a medium for said method; and an agent for use in said medium.

A determination method of non-destructively and easily determining a state of an aggregate of a plurality of cells formed by three-dimensional culture is provided. A determination method according to the disclosed technology includes generating a phase difference image of an aggregate of a plurality of cells from a hologram obtained by imaging the aggregate, deriving a phase difference amount density by dividing a total phase difference amount that is a value obtained by integrating a phase difference amount of each of a plurality of pixels constituting the phase difference image by a volume of the aggregate, and determining a state of the aggregate on the basis of a time transition of the phase difference amount density.

The disclosure relates to Bovine germplasm of Bos taurus variety JE840003146074527. Included in the present disclosure are cells comprising the Bovine variety JE840003146074527. Also provided by the present disclosure are tissue cultures of cells, animals obtained from said cells, and parts thereof, including F1 spermatozoa. The disclosure further provides for methods of breeding, selecting, and using the germplasm to improve existing commercial cattle herds generated from in vitro fertilization methods and progeny cattle obtained from in vitro fertilization and implantation and artificial insemination methods.

The disclosure relates to Bovine germplasm of Bos taurus variety JE840003146074527. Included in the present disclosure are cells comprising the Bovine variety JE840003146074527. Also provided by the present disclosure are tissue cultures of cells, animals obtained from said cells, and parts thereof, including F1 spermatozoa. The disclosure further provides for methods of breeding, selecting, and using the germplasm to improve existing commercial cattle herds generated from in vitro fertilization methods and progeny cattle obtained from in vitro fertilization and implantation and artificial insemination methods.

An object of the present invention is to provide a method for producing a pluripotent stem cell that can efficiently differentiate into a target differentiated cell. According to the present invention, a method for producing a cell is provided, the method including a first step of obtaining an undifferentiated cell which is obtained by introducing a reprogramming factor into a somatic cell and has a relatively low ability to differentiate into a specific differentiated cell; and a second step of treating the cell while maintaining an undifferentiated state of the cell to obtain a cell having a relatively high ability to differentiate into the specific differentiated cell.

Disclosed are methods and compositions for in situ germline genome engineering. The disclosed methods and compositions may be utilized for germline genome engineering in a subject having a reproductive organ containing a fertilized zygote, via: (i) isolating or obtaining the reproductive organ from the subject after a time period following insemination of the subject; (ii) introducing a reagent composition into the reproductive organ, the reagent composition comprising a nuclease system and/or an exogeneous polynucleotide; and (iii) electroporating the reproductive organ.

The present invention relates to a method for differentiating hair follicle cells into germline stem cells, germline stem cells differentiated by the method, and use of the same germline stem cells. A method of differentiating hair follicle cells into germline stem cells according to the present invention can differentiate hair follicle cells into germline stem cells using culture conditions only, without genetic modification. Capable of inducing differentiation of cells of specific individual types, such as hair follicle cells, into cells of different types such as germline cells, the present invention is therefore expected to be usefully used for the understanding of reproductive biology and the clinical application thereof.